Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC.

Saved in:
Bibliographic Details
Title: Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC.
Authors: Ryan SL; The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia., Beard S; The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia., Barr MP; Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland; Thoracic Oncology Research Group, Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, St. James's Hospital and Trinity College Dublin, Dublin, Ireland., Umezawa K; Department of Molecular Target Medicine, Aichi Medical University, Nagakute, Japan., Heavey S; Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland; Division of Surgery and Interventional Sciences, University College London, United Kingdom., Godwin P; Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland., Gray SG; Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland; Thoracic Oncology Research Group, Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, St. James's Hospital and Trinity College Dublin, Dublin, Ireland., Cormican D; Department of Histopathology and Morbid Anatomy, School of Medicine, Trinity College Dublin, Dublin, Ireland., Finn SP; Department of Histopathology and Morbid Anatomy, School of Medicine, Trinity College Dublin, Dublin, Ireland; Department of Histopathology, Labmed Directorate, St. James's Hospital, Dublin, Ireland., Gately KA; Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland; Thoracic Oncology Research Group, Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, St. James's Hospital and Trinity College Dublin, Dublin, Ireland., Davies AM; Vale Life Sciences Pty., Translational Research Institute, Brisbane, Australia., Thompson EW; The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia., Richard DJ; The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia., O'Byrne KJ; The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia; Princess Alexandra Hospital, Brisbane, Australia., Adams MN; The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia. Electronic address: mn.adams@qut.edu.au., Baird AM; The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia; Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland; Thoracic Oncology Research Group, Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, St. James's Hospital and Trinity College Dublin, Dublin, Ireland. Electronic address: bairda@tcd.ie.
Source: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2019 Sep; Vol. 135, pp. 217-227. Date of Electronic Publication: 2019 Jul 12.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1872-8332
DOI:10.1016/j.lungcan.2019.07.006